These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 30227129)

  • 1. Multimodality Therapy for N2 Non-Small Cell Lung Cancer: An Evolving Paradigm.
    Spicer JD; Shewale JB; Nelson DB; Mitchell KG; Bott MJ; Vallières E; Wilshire CL; Vaporciyan AA; Swisher SG; Jones DR; Darling GE; Sepesi B
    Ann Thorac Surg; 2019 Jan; 107(1):277-284. PubMed ID: 30227129
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Patterns of disease failure after trimodality therapy of nonsmall cell lung carcinoma pathologic stage IIIA (N2). Analysis of Cancer and Leukemia Group B Protocol 8935.
    Kumar P; Herndon J; Langer M; Kohman LJ; Elias AD; Kass FC; Eaton WL; Seagren SL; Green MR; Sugarbaker DJ
    Cancer; 1996 Jun; 77(11):2393-9. PubMed ID: 8635112
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Induction Chemoradiotherapy (50 Gy), Followed by Resection, for Stage IIIA-N2 Non-Small Cell Lung Cancer.
    Tanaka F; Yokomise H; Soejima T; Uramoto H; Yamanaka T; Nakagawa K; Yamamoto N; Nishimura Y; Niwa H; Okada M; Nakagawa T; Yamashita M
    Ann Thorac Surg; 2018 Oct; 106(4):1018-1024. PubMed ID: 29890150
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Adjuvant therapy following induction therapy and surgery improves survival in N2-positive non-small cell lung cancer.
    White AA; Lee DN; Mazzola E; Kucukak S; Polhemus E; Jaklitsch MT; Mentzer SJ; Wee JO; Bueno R; Swanson SJ
    J Surg Oncol; 2021 Feb; 123(2):579-586. PubMed ID: 33259637
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Adding Radiotherapy to Adjuvant Chemotherapy Does Not Improve Survival of Patients With N2 Lung Cancer.
    Drake JA; Portnoy DC; Tauer K; Weksler B
    Ann Thorac Surg; 2018 Oct; 106(4):959-965. PubMed ID: 29856974
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The role of consolidation therapy for stage III non-small cell lung cancer with persistent N2 disease after induction chemotherapy.
    Amini A; Correa AM; Komaki R; Chang JY; Tsao AS; Roth JA; Swisher SG; Rice DC; Vaporciyan AA; Lin SH
    Ann Thorac Surg; 2012 Sep; 94(3):914-20. PubMed ID: 22819472
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment rationale and design of the induction chemotherapy and adjuvant thoracic radiation in resectable N2-3A/3B non-small cell lung cancer (ICAT) study.
    Tsunezuka H; Inoue M
    Medicine (Baltimore); 2019 Jul; 98(27):e16298. PubMed ID: 31277165
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Patterns of Locoregional Relapses in Patients with Contemporarily Staged Stage III-N2 NSCLC Treated with Induction Chemotherapy and Resection: Implications for Postoperative Radiotherapy Target Volumes.
    Billiet C; De Ruysscher D; Peeters S; Decaluwé H; Vansteenkiste J; Dooms C; Deroose CM; De Leyn P; Hendrikx M; Bulens P; Le Péchoux C; Mebis J
    J Thorac Oncol; 2016 Sep; 11(9):1538-49. PubMed ID: 27374454
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Postoperative Radiotherapy for Surgically Resected ypN2 Non-Small Cell Lung Cancer.
    Brandt WS; Yan W; Leeman JE; Tan KS; Park BJ; Adusumilli PS; Bott MJ; Molena D; Isbell J; Chaft J; Rimner A; Jones DR
    Ann Thorac Surg; 2018 Sep; 106(3):848-855. PubMed ID: 29807005
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Locoregional Control, Overall Survival, and Disease-Free Survival in Stage IIIA (N2) Non-Small-Cell Lung Cancer: Analysis of Resected and Unresected Patients.
    Rajaram R; Correa AM; Xu T; Nguyen QN; Antonoff MB; Rice D; Mehran R; Roth J; Walsh G; Swisher S; Hofstetter WL; Vaporciyan A; Cascone T; Tsao AS; Papadimitrakopoulou VA; Gandhi S; Liao Z; Sepesi B
    Clin Lung Cancer; 2020 Jul; 21(4):e294-e301. PubMed ID: 32089476
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Role of postoperative radiotherapy after curative resection and adjuvant chemotherapy for patients with pathological stage N2 non-small-cell lung cancer: a propensity score matching analysis.
    Kim BH; Kim HJ; Wu HG; Kang CH; Kim YT; Lee SH; Kim DW
    Clin Lung Cancer; 2014 Sep; 15(5):356-64. PubMed ID: 24996882
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The impact of residual multi-level N2 disease after induction therapy for non-small cell lung cancer.
    Sawabata N; Keller SM; Matsumura A; Kawashima O; Hirono T; Osaka Y; Maeda H; Fukai S; Kawahara M;
    Lung Cancer; 2003 Oct; 42(1):69-77. PubMed ID: 14512190
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Postoperative radiotherapy is effective in improving survival of patients with stage pIII-N2 non-small-cell lung Cancer after pneumonectomy.
    Wang W; Men Y; Wang J; Zhou Z; Chen D; Xiao Z; Feng Q; Lv J; Liang J; Bi N; Gao S; Wang L; Hui Z
    BMC Cancer; 2019 May; 19(1):478. PubMed ID: 31113432
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Analysis of Patients Unable to Undergo Adjuvant Chemotherapy after Surgery in Stage IIIA/B Non-Small Cell Lung Cancer: Will They Benefit from Mediastinal Radiotherapy?
    Graeter TP; Sebastian B; Bischof M; Kugler G; Fischer JR; Schneider T
    Thorac Cardiovasc Surg; 2016 Sep; 64(6):501-6. PubMed ID: 26322832
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combined treatment modalities in Pancoast tumor: results of a monocentric retrospective study.
    Jeannin G; Merle P; Janicot H; Thibonnier L; Kwiatkowski F; Naame A; Chadeyras JB; Galvaing G; Belliere A; Filaire M; Verrelle P
    Chin Clin Oncol; 2015 Dec; 4(4):39. PubMed ID: 26730751
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic Significance of the Number of Metastatic pN2 Lymph Nodes in Stage IIIA-N2 Non-Small-Cell Lung Cancer After Curative Resection.
    Yoo C; Yoon S; Lee DH; Park SI; Kim DK; Kim YH; Kim HR; Choi SH; Kim WS; Choi CM; Jang SJ; Song SY; Kim SS; Choi EK; Lee JC; Suh C; Lee JS; Kim SW
    Clin Lung Cancer; 2015 Nov; 16(6):e203-12. PubMed ID: 25997733
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase III study comparing chemotherapy and radiotherapy with preoperative chemotherapy and surgical resection in patients with non-small-cell lung cancer with spread to mediastinal lymph nodes (N2); final report of RTOG 89-01. Radiation Therapy Oncology Group.
    Johnstone DW; Byhardt RW; Ettinger D; Scott CB
    Int J Radiat Oncol Biol Phys; 2002 Oct; 54(2):365-9. PubMed ID: 12243809
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pneumonectomy in Stage IIIA-N2 NSCLC: Should It Be Considered After Neoadjuvant Chemotherapy?
    Casiraghi M; Guarize J; Sandri A; Maisonneuve P; Brambilla D; Romano R; Galetta D; Petrella F; Gasparri R; Gridelli C; De Marinis F; Spaggiari L
    Clin Lung Cancer; 2019 Mar; 20(2):97-106.e1. PubMed ID: 30446406
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Early-stage non-small-cell lung cancer: current perspectives in combined-modality therapy.
    Bunn PA
    Clin Lung Cancer; 2004 Sep; 6(2):85-98. PubMed ID: 15476594
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Preoperative concurrent chemoradiotherapy followed by extrapleural pneumonectomy for patients with non-small cell lung cancer with malignant pleural effusion and/or pleural nodules: Ten-year results of a prematurely terminated single institute phase II trial.
    Yamaguchi M; Ichinose Y; Shimamatsu S; Yoshida T; Toyokawa G; Nosaki K; Hirai F; Seto T; Takenoyama M
    Surg Oncol; 2015 Jun; 24(2):78-83. PubMed ID: 25818753
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.